Skip to main content

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA - (NewMediaWire) - November 14, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the third quarter of 2022.  These results, including the financial statements included herein, can be found in the Company’s Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission. 

Third Quarter 2022 Financial Results

All comparisons are made on a year-over-year basis.

  • Revenues. The Company generated $42,269 and $98,999 in revenues for the three months ended September 30, 2022 and 2021, respectively. The decrease in revenues was mainly due to the completion of certain contract services during Q3 2021.

  • Operating Expenses increased by $1,678,209, or 81%, to $3,747,369 for the three months ended September 30, 2022 from $2,069,160 for the three months ended September 30, 2021. Such increase in operating expenses was mainly attributable to the increase in selling, general and administrative expenses by $1,636,150 which relates to costs in conjunction with our recent stock issuance and increase in research and development expenses of $42,059 to continue developing our pipeline.

  • Other Income (Expense) Our other (expense) income was $(56,461) for the three months ended September 30, 2022, compared to $8,643 for the three months ended September 30, 2021. The change was principally caused by the increase in interest expense, while being offset by the increase in interest income for the three months ended September 30, 2022, and loss on investment in equity securities and government grant income for the three months ended September 30, 2021.

  • Net Interest income (Expense) was $(78,372) for the three months ended September 30, 2022, compared to $(29,344) for the three months ended September 30, 2021. The increase of $49,028, or approximately 167%, was primarily due to the increase in interest expense due to recognition of interest expense for the converted notes for proper accounting purposes.

  • Net Loss. As a result of the above factors, our net loss was $3,776,524 for the three months ended September 30, 2022 compared to $1,886,244 for the three months ended September 30, 2021, representing a decrease of $1,890,280, or 100%.

Recent Operational Highlights

Vitargus® Phase II Study

  • Australia: Vitargus® Phase II Clinical Study protocol documents were accepted by the Australian Bellberry Human Research Ethics Committee (“HREC”) and a Clinical Trial Notification (“CTN”) was submitted to the Australian Therapeutic Goods Administration (TGA) to initiate the study in Australia.

  • Thailand: On August 2, 2022, the Ethics Committee (EC) of the Ramathibodi Hospital, Mahidol University provided approval allowing the hospital to conduct the Vitargus Phase II Study. This follows a similar approval received on July 18, 2022, by Srinagarind Hospital, Khon Kaen University of Thailand. On November 2, 2022, both hospitals received Thai FDA investigational product (IP) import licenses allowing them to initiate the clinical study in Thailand.

ADHD Phase II Part 2 Clinical Update

  • Taiwan: The Phase II Part 2 clinical study of the Company’s ADHD medicine, ABV-1505 has been initiated at five prestigious medical centers in Taiwan. The Part 2 study is a randomized, double-blind, placebo-controlled study, titled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part 2”. Thirty-five subjects have already been enrolled including 20 subjects who have completed the 56-day treatment. It is expected that eventually approximately 100 patients in Taiwan and the United States will participate in the study.

  • United States: The University of California, San Francisco (UCSF) Medical Center Institutional Review Board has approved participation in the Part 2 study, set to begin in the first quarter of 2023. Part 1 of the Phase II study of ABV-1505 was conducted at UCSF from January 2020 through July 2020 and was accepted by the US Food & Drug Administration in October of 2020.

Other Developments

  • On October 20, 2022, ABVC received a Notice of Allowance for ABV-1504 from the US Patent and Trademark Office that substantially extends the existing patent life of ABV-1504 to the year 2041.  The patent, entitled “Polygala Extract for the Treatment of Major Depressive Disorder,” outlines a method for treating major depressive disorder by oral administration of a composition, ABV-1504, containing Radix Polygalae (Polygala tenuifolia Willd). The polygala extract, designated PDC-1421, is the key active ingredient in ABV-1504 which was orally administered to healthy volunteers and proved to be safe and well-tolerated for a daily dose from 380 mg to 3800 mg. The completed Phase II clinical study indicated that the drug can be administered chronically over at least 42 days with the daily dose administered three times per day, wherein each dose contains from 380 mg to 760 mg of the botanical extraction.

  • The Cedars-Sinai Medical Center (CSMC, West Hollywood CA) Institutional Review Board (IRB) has approved their institution joining the Phase I study of ABV-1601 for treating depression in cancer patients. The Principal Investigator of the CSMC study will be Dr. Scott A. Irwin, MD, PhD., an eminent Professor of Psychiatry & Behavioral Neurosciences. The Phase I study is open label and will be conducted with 12 cancer patients with moderate to severe depressive symptoms. The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601. The second objective is to determine the most effective dosages for a randomized, double-blind, non-inferiority Phase II trial of PDC-1421 that ABVC expects to initiate in 2023. The Company then intends to compare results of the Phase II study of ABV-1601 to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.

About ABVC BioPharma, Inc.

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

Forward-Looking Statements

Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists;  (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates; and (vi) impact of COVID-19 pandemic on our business, results of operations, financial condition and cash flows. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

Contact:

Leeds Chow

CFO

Email: leedschow@ambrivis.com


ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

Current Assets

 

 

 

 

 

Cash and cash equivalents

$

1,323,543

 

 

$

5,828,548

 

Restricted cash and cash equivalents

 

646,604

 

 

 

736,667

 

Accounts receivable, net

 

47,680

 

 

 

280,692

 

Accounts receivable - related parties, net

 

-

 

 

 

145,399

 

Due from related party - Current

 

500,000

 

 

 

-

 

Inventory, net

 

20,489

 

 

 

25,975

 

Short-term Investment

 

77,583

 

 

 

108,147

 

Prepaid expense and other current assets

 

287,181

 

 

 

528,354

 

Total Current Assets

 

2,903,080

 

 

 

7,653,782

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

566,751

 

 

 

525,881

 

Operating lease right-of-use assets

 

1,243,930

 

 

 

1,471,899

 

Goodwill, net

 

-

 

 

 

-

 

Long-term investments

 

816,160

 

 

 

932,755

 

Deferred tax assets

 

1,013,159

 

 

 

981,912

 

Prepaid expenses - noncurrent

 

103,218

 

 

 

119,309

 

Security deposits

 

57,656

 

 

 

41,157

 

Prepayment for long-term investments

 

2,586,358

 

 

 

1,153,155

 

Due from related parties - noncurrent

 

1,190,255

 

 

 

818,183

 

Total Assets

$

10,480,567

 

 

$

13,698,033

 

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

Current Liabilities

 

 

 

 

 

Short-term bank loans

$

1,866,250

 

 

$

1,640,000

 

Accrued expenses and other current liabilities

 

1,201,497

 

 

 

1,300,803

 

Advance from customers

 

10,985

 

 

 

10,985

 

Operating lease liability – current portion

 

363,752

 

 

 

347,100

 

Due to related parties

 

451,826

 

 

 

393,424

 

Total Current Liabilities

 

3,894,310

 

 

 

3,692,312

 

 

 

 

 

 

 

 

 

Tenant security deposit

 

12,880

 

 

 

10,580

 

Operating lease liability – noncurrent portion

 

880,178

 

 

 

1,124,799

 

Total Liabilities

 

4,787,368

 

 

 

4,827,691

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding

 

-

 

 

 

-

 

Common stock, $0.001 par value, 100,000,000 authorized, 32,632,329 and 28,926,322 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

 

32,632

 

 

 

28,926

 

Additional paid-in capital

 

66,493,649

 

 

 

58,113,667

 

Stock subscription receivable

 

(1,580,180

)

 

 

(2,257,400

)

Accumulated deficit

 

(50,040,501

)

 

 

(38,481,200

)

Accumulated other comprehensive income

 

113,081

 

 

 

539,660

 

Treasury stock

 

(9,100,000

)

 

 

(9,100,000

)

Total Stockholders’ equity

 

5,918,681

 

 

 

8,843,653

 

Noncontrolling Interest

 

(225,482

)

 

 

26,689

 

Total Equity

 

5,693,199

 

 

 

8,870,342

 

 

 

 

 

 

 

 

 

Total Liabilities and Equity

$

10,480,567

 

 

$

13,698,033

 

 

 

 

 

 

 

 

 

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue

$

42,269

 

 

$

98,999

 

 

$

380,789

 

 

$

393,590

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

10,741

 

 

 

393

 

 

 

21,004

 

 

 

2,284

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

31,528

 

 

 

98,606

 

 

 

359,785

 

 

 

391,306

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

3,216,146

 

 

 

1,579,996

 

 

 

6,000,055

 

 

 

3,979,283

 

Research and development expenses

 

305,483

 

 

 

263,424

 

 

 

1,197,669

 

 

 

743,617

 

Stock based compensation

 

225,740

 

 

 

225,740

 

 

 

5,143,483

 

 

 

927,220

 

Total operating expenses

 

3,747,369

 

 

 

2,069,160

 

 

 

12,341,207

 

 

 

5,650,120

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(3,715,841

)

 

 

(1,970,554

)

 

 

(11,981,422

)

 

 

(5,258,814

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

48,165

 

 

 

9,333

 

 

 

127,354

 

 

 

72,584

 

Interest expense

 

(126,537

)

 

 

(38,677

)

 

 

(159,507

)

 

 

(251,577

)

Operating sublease income

 

21,597

 

 

 

2,624

 

 

 

78,523

 

 

 

60,822

 

Operating sublease income - related parties

 

-

 

 

 

1,200

 

 

 

-

 

 

 

3,600

 

Gain/Loss on foreign exchange changes

 

(177

)

 

 

(5,999

)

 

 

17,865

 

 

 

(10,806

)

Gain/Loss on investment in equity securities

 

-

 

 

 

(91,765

)

 

 

-

 

 

 

(193,147

)

Other (expense) income

 

491

 

 

 

(404

)

 

 

(59,381

)

 

 

(171

)

Government grant income

 

-

 

 

 

132,331

 

 

 

-

 

 

 

256,731

 

Total other income (expense)

 

(56,461

)

 

 

8,643

 

 

 

4,854

 

 

 

(61,964

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before provision for income tax

 

(3,772,302

)

 

 

(1,961,911

)

 

 

(11,976,568

)

 

 

(5,320,778

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income tax

 

4,222

 

 

 

(75,667

)

 

 

(165,096

)

 

 

(186,255

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(3,776,524

)

 

 

(1,886,244

)

 

 

(11,811,472

)

 

 

(5,134,523

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to noncontrolling interests

 

(71,660

)

 

 

(79,756

)

 

 

(252,171

)

 

 

(227,964

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributed to ABVC and subsidiaries

 

(3,704,864

)

 

 

(1,806,488

)

 

 

(11,559,301

)

 

 

(4,906,559

)

Foreign currency translation adjustment

 

(190,019

)

 

 

16,138

 

 

 

(426,579

)

 

 

416,859

 

Comprehensive loss

$

(3,894,883

)

 

$

(1,790,351

)

 

$

(11,985,880

)

 

$

(4,489,700

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

$

(0.11

)

 

$

(0.07

)

 

$

(0.37

)

 

$

(0.20

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic and diluted

 

32,574,551

 

 

 

26,882,181

 

 

 

31,193,397

 

 

 

25,053,522

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

 

 

 

2022

 

 

2021

 

Cash flows from operating activities

 

 

 

 

 

Net loss

 

$

(11,811,472

)

 

$

(5,134,523

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

Depreciation

 

17,364

 

 

 

8,725

 

Stock based compensation for non employees

 

5,143,483

 

 

 

927,220

 

Gain/Loss on investment in equity securities

 

-

 

 

 

193,147

 

Government grant income

 

-

 

 

 

(256,731

)

Provision for doubtful accounts

 

521,955

 

 

 

-

 

Other non-cash income and expenses

 

30,564

 

 

 

-

 

Deferred tax

 

(31,247

)

 

 

(187,055

)

Changes in operating assets and liabilities:

 

 

 

 

 

Decrease (increase) in accounts receivable

 

(31,909

)

 

 

(171,655

)

Decrease (increase) in prepaid expenses and deposits

 

243,065

 

 

 

(647,219

)

Decrease (increase) in due from related parties

 

(983,707

)

 

 

422,651

 

Decrease (increase) in inventory

 

5,486

 

 

 

(59,673

)

Increase (decrease) in accounts payable

 

-

 

 

 

(6,547

)

Increase (decrease) in accrued expenses and other current liabilities

(99,306

)

 

 

(338,928

)

Increase (decrease) in advanced from others

 

-

 

 

 

(1,085

)

Increase (decrease) in due to related parties

 

58,402

 

 

 

178,570

 

Net cash used in operating activities

 

(6,937,322

)

 

 

(5,073,103

)

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

Purchase of equipment

 

(119,603

)

 

 

-

 

Purchase of investment

 

-

 

 

 

(110,700

)

Purchase of property, plant and equipment

 

-

 

 

 

(18,503

)

Prepayment for equity investment

 

(1,518,793

)

 

 

(1,104,609

)

Net cash used in investing activities

 

(1,638,396

)

 

 

(1,233,812

)

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

Issuance of common stock

 

3,917,425

 

 

 

6,875,000

 

Payment for offering costs

 

-

 

 

 

(850,429

)

Proceeds from short-term loan

 

350,000

 

 

 

-

 

Repayment of convertible notes

 

-

 

 

 

(306,836

)

Repayment of short-term loan

 

-

 

 

 

(100,000

)

Repayment of notes payable

 

-

 

 

 

(107,100

)

Proceeds from long-term loan

 

-

 

 

 

236,498

 

Repayment of long-term bank loans

 

-

 

 

 

(4,396

)

Net cash provided by (used in) financing activities

 

4,267,425

 

 

 

5,742,737

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents and restricted cash

 

(286,775

)

 

 

11,579

 

 

 

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents and restricted cash

 

(4,595,068

)

 

 

(552,599

)

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents and restricted cash

 

 

 

 

 

Beginning

 

 

6,565,215

 

 

 

5,001,371

 

Ending

 

 

$

1,970,147

 

 

$

4,448,772

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flows

 

 

 

 

 

Cash paid during the year for:

 

 

 

 

 

Interest expense paid

$

161,741

 

 

$

327,642

 

Income taxes paid

$

1,600

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.